- Home
- WRAP vs IMAB Comparison
WRAP vs IMAB Comparison
Compare WRAP & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRAP
- IMAB
- Stock Information
- Founded
- WRAP 2016
- IMAB 2014
- Country
- WRAP United States
- IMAB United States
- Employees
- WRAP N/A
- IMAB N/A
- Industry
- WRAP Ordnance And Accessories
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- WRAP Industrials
- IMAB Health Care
- Exchange
- WRAP Nasdaq
- IMAB Nasdaq
- Market Cap
- WRAP 74.7M
- IMAB 73.9M
- IPO Year
- WRAP N/A
- IMAB 2020
- Fundamental
- Price
- WRAP $1.44
- IMAB $1.30
- Analyst Decision
- WRAP
- IMAB Strong Buy
- Analyst Count
- WRAP 0
- IMAB 2
- Target Price
- WRAP N/A
- IMAB $5.50
- AVG Volume (30 Days)
- WRAP 124.8K
- IMAB 238.6K
- Earning Date
- WRAP 05-15-2025
- IMAB 05-15-2025
- Dividend Yield
- WRAP N/A
- IMAB N/A
- EPS Growth
- WRAP N/A
- IMAB N/A
- EPS
- WRAP N/A
- IMAB N/A
- Revenue
- WRAP $3,796,000.00
- IMAB N/A
- Revenue This Year
- WRAP N/A
- IMAB N/A
- Revenue Next Year
- WRAP N/A
- IMAB N/A
- P/E Ratio
- WRAP N/A
- IMAB N/A
- Revenue Growth
- WRAP N/A
- IMAB N/A
- 52 Week Low
- WRAP $1.21
- IMAB $0.60
- 52 Week High
- WRAP $2.58
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- WRAP 44.91
- IMAB 75.39
- Support Level
- WRAP $1.30
- IMAB $0.90
- Resistance Level
- WRAP $1.50
- IMAB $1.47
- Average True Range (ATR)
- WRAP 0.09
- IMAB 0.10
- MACD
- WRAP 0.01
- IMAB 0.04
- Stochastic Oscillator
- WRAP 48.21
- IMAB 72.45
About WRAP Wrap Technologies Inc.
Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel worldwide. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).